1. Net revenues for the quarter were ₹348.6 Cr (4.6% growth YoY). EBITDA for the quarter stood at ₹73.4 Cr and EBITDA margin for the quarter was 21.1%.PAT for the quarter was ₹33 Cr and PAT margins were 9.5%.
2. Revenues from domestic formulation business for the quarter was ₹181.5 Cr (15.2% growth YoY). Major therapeutic segments viz. anti-infectives, gastrointestinal, urological and respiratory performed well.
3. Revenues from international formulation business were flat YoY. US business was ₹49.1 Cr(9.6% growth YoY) which was the highest among the past 3 quarters. Revenues from Europe were ₹54.3 Cr. Revenues from Emerging Markets were ₹34.3 Cr Cr (27.9% growth YoY).
4. Revenues from the API business remained flat at ₹19.69 Cr. Revenue for AnaCipher CRO and Analytical Services were ₹4.4 Cr (43.4% growth YoY)
5. For the domestic formulation business, in Q1 of FY22 they benefited from the COVID wave. In Q2 they had a strong quarter because of seasonal effects, but in Q3 they did not have any support and both the COVID and non-COVID products have done well.
6. The guidance for domestic formulations for the full year was ₹850 Cr. So far in 9 months they have done ₹610 Cr. They are confident about the 4th quarter, they may not be able to reach ₹850 Cr but they will come close to it.
7. Q3 was not on track for the European business - the main reason was because API price of paracetamol had shot up so they had to slow down on that molecule. But things have come back on track and they are expecting Q4 to go well.
Target for Europe for the year was ₹300 Cr and management think ₹285-290 Cr is doable. Target for the US for this year was ₹250 Cr, they are now targeting ₹225-230 Cr due to RM and logistics disruptions.
8. The CRO business is profitable at the EBITDA level. It is a small scale CRO but meets their needs. Indoco has filed several first to file products from there.
Indoco currently uses 50-60% of the CRO capacity and the rest is used for external clients. They have plans to double its capacity over the next financial year.
9. They can’t pass on RM price increases because they are into branded generics and it is not easy to pass on. They had anticipated the increase in prices and stocked up inventory which they used for the first 2 quarters.
But in the 3rd quarter the price increase affected them.
10. They can take price increases in non schedule drugs upto 9-10% per annum but scheduled drugs goes along with the government directive. They have taken an average of 4.9% price increase in the India portfolio.
10. They can take price increases in non schedule drugs upto 9-10% per annum but scheduled drugs goes along with the government directive. They have taken an average of 4.9% price increase in the India portfolio.
11. Teva’s market share in Brinzolamide is close to 22%. None of the profit share for this product has been accounted for. It will be recognized at the end of March.
The order book for Europe is very strong at ₹120 Cr. So they don’t have issues on the demand side. They are planning for the efficient execution of this.
12. The domestic formulation sales look flat compared to Q3 FY20 because febrex plus which is a major brand for the company is not yet back to the pre-pandemic levels.
13. 11% of the product portfolio falls under NLEM. They will be taking a 10% price increase across the NLEM portfolio. For non-NLEM portfolio, they will take price increases in brands where they rank in the top 3.
12. RM prices have stabilized but they are not coming down. So they need price increases to improve margins.
13. In Africa they have a branded generics model and they have their own front end which is expected to do ₹40-42 Cr of sales for the whole year.
They have just stepped into that business so they do not want to increase prices just yet. In other countries they have already started asking for price rise and are getting a favorable response from the front end.
14. They are observing a lot of value add from new launches which is a good thing because their product portfolio is mostly made up of legacy products. The new launches will not only help them grow but also restructure their portfolio.
15. They have a very good balance of COVID and non-COVID products and both the product basket have grown very well. They may see a small downside next year if there are no further COVID waves because products like Karvol Plus and ATM may slow down.
16. Margins are expected to improve next year due to an increase in MR productivity. It is at ₹2.8 lakh currently. They will be able to cross ₹3 lakh next year.
17. In the US market, they have 7-8 injectables, about 5-6 ophthalmics and 4 solid dosages. Most of the products are doing well.
18. They are adding capacities on the suspension side; a new line is about to be commissioned in March at Goa Plant 2 which will increase the capacity by 33%. Current capacity utilization is at 75-80%.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
